Biora Therapeutics, Inc.
BIOR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $32 | $318 | $542 | $872 |
| % Growth | -89.9% | -41.3% | -37.8% | – |
| Cost of Goods Sold | $0 | $110 | $0 | $117 |
| Gross Profit | $32 | $208 | $542 | -$117 |
| % Margin | 100% | 65.4% | 100% | -13.4% |
| R&D Expenses | $5,610 | $7,704 | $7,005 | $6,118 |
| G&A Expenses | $0 | $0 | $0 | $8,356 |
| SG&A Expenses | $10,649 | $8,400 | $9,053 | $7,109 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$1,247 |
| Other Operating Expenses | $0 | -$110 | $0 | $0 |
| Operating Expenses | $16,259 | $15,994 | $16,058 | $13,227 |
| Operating Income | -$16,227 | -$15,786 | -$15,516 | -$13,344 |
| % Margin | -50,709.4% | -4,964.2% | -2,862.7% | -1,530.3% |
| Other Income/Exp. Net | -$6,035 | $22,184 | $11,375 | -$2,383 |
| Pre-Tax Income | -$22,262 | $6,398 | -$4,141 | -$15,727 |
| Tax Expense | -$44 | -$67 | $48 | -$95 |
| Net Income | -$18,402 | $6,465 | -$4,189 | -$15,413 |
| % Margin | -57,506.3% | 2,033% | -772.9% | -1,767.5% |
| EPS | -5.04 | -0 | -0.14 | -0.62 |
| % Growth | -5,039,900% | 99.9% | 77.4% | – |
| EPS Diluted | -5.04 | 0 | -0.14 | -0.62 |
| Weighted Avg Shares Out | 3,653 | 35,720,168 | 29,297 | 24,811 |
| Weighted Avg Shares Out Dil | 3,653 | 74,215,969 | 29,297 | 24,811 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,016 | $711 | $2,757 | $1,840 |
| Depreciation & Amortization | $4,019 | $110 | $105 | $117 |
| EBITDA | -$16,227 | $7,219 | -$1,279 | -$13,770 |
| % Margin | -50,709.4% | 2,270.1% | -236% | -1,579.1% |